Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 38.00
Bid: 37.00
Ask: 39.00
Change: -1.00 (-2.56%)
Spread: 2.00 (5.405%)
Open: 39.00
High: 39.00
Low: 38.00
Prev. Close: 39.00
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sareum Cautiously Optimistic As It Posts Widened First Half Loss

Wed, 25th Feb 2015 11:32

LONDON (Alliance News) - Sareum Holdings PLC Wednesday expressed "cautious optimism" for its future as it has reached a "critical stage" in its drug development programmes, although increased investment in its research programme caused its pretax loss to widen in the first half of its financial year.

The company posted a pretax loss of GBP749,000 for the six months to end-December, compared with a pretax loss of GBP375,000 a year earlier, which it attributed to increased investment in its research programme as they reach more advanced stages of development. It is not yet producing any revenue.

The specialist cancer drug business said its Checkpoint Kinase 1 programme, targeting lung, pancreatic, and other cancers, is nearing completion of toxicology studies. After these results it will submit an application to begin a Phase I clinical trial, which it expects to take place in the first half of its next financial year to end-June 2016, and will trigger a financial commitment of up to GBP795,500 from Sareum.

Sareum said it was also making good progress with its TYK3 and Aurora+FLT3 development programmes, having secured several key patents in some markets.

The company said that the next phase of its business could be "transformative in terms of the company reaching its goal of delivering a clinical-stage research programme. Later stage programmes achieve higher asset values and, while there is always risk with any drug development, there is also significant potential upside," the company said.

It is continuing to talk to licence partners on potential commercialisation of its compounds, and said that to maintain its product pipeline it is continuing to investigate sources of new research opportunities.

"We are extremely pleased with the progress that has been made in the last six months across all our programmes, and CHK1 in particular which is reaching a crucial phase of development as it nears its first in-human trials," said Chief Executive Officer Tim Mitchell in a statement.

Still shares in Sareum are trading down 16.7% at 0.375 pence Wednesday morning, its lowest level since February 6.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
23 Apr 2021 12:17

Sareum shares rise after improved interim results, research progress

Sareum shares rise after improved interim results, research progress

Read more
16 Feb 2021 13:56

IN BRIEF: Sareum Notes Launch Of UK Government's Agile Platform

IN BRIEF: Sareum Notes Launch Of UK Government's Agile Platform

Read more
7 Jan 2021 12:52

Sareum gets approval for US patent application

(Sharecast News) - Specialist drug development company Sareum announced on Thursday that the United States Patent and Trademark Office has now formally approved its patent application, number 16/351,620.

Read more
7 Jan 2021 10:51

UK WINNERS & LOSERS SUMMARY: Mitchells & Butlers Down Amid Raise Plan

UK WINNERS & LOSERS SUMMARY: Mitchells & Butlers Down Amid Raise Plan

Read more
7 Jan 2021 09:53

Sareum Shares Rise On Granting Of Patent For SDC-1802 Inhibitor

Sareum Shares Rise On Granting Of Patent For SDC-1802 Inhibitor

Read more
16 Dec 2020 22:00

IN BRIEF: Sareum Makes Progress On Potential Covid Treatment Candidate

IN BRIEF: Sareum Makes Progress On Potential Covid Treatment Candidate

Read more
14 Dec 2020 12:27

Sareum Shares Surge 30% After Study Results Support Covid-19 Programme

Sareum Shares Surge 30% After Study Results Support Covid-19 Programme

Read more
8 Dec 2020 15:51

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
3 Dec 2020 15:45

IN BRIEF: Sareum Gets GBP174,000 To Research Potential Virus Treatment

IN BRIEF: Sareum Gets GBP174,000 To Research Potential Virus Treatment

Read more
3 Dec 2020 12:19

Sareum Holdings secures grant for Covid-19 treatment project

(Sharecast News) - Specialist drug development company Sareum Holdings announced on Thursday that the grant offer letter from UK Research and Innovation (UKRI) had now been received and approved.

Read more
12 Nov 2020 19:17

UK TRADING UPDATE SUMMARY: Clipper Expects 20% Interim Revenue Climb

UK TRADING UPDATE SUMMARY: Clipper Expects 20% Interim Revenue Climb

Read more
27 Oct 2020 15:16

IN BRIEF: Sareum Nets Covid-19 Therapy UK Research Grant

IN BRIEF: Sareum Nets Covid-19 Therapy UK Research Grant

Read more
13 Oct 2020 13:54

IN BRIEF: Sareum Loss Narrows On Reduced Administration Expenses

IN BRIEF: Sareum Loss Narrows On Reduced Administration Expenses

Read more
8 Oct 2020 19:54

UK TRADING UPDATE SUMMARY: Motorpoint Predicts Local Lockdowns Bite

UK TRADING UPDATE SUMMARY: Motorpoint Predicts Local Lockdowns Bite

Read more
8 Oct 2020 15:50

Sareum to get US patent on SDC-1802 programme

(Sharecast News) - Specialist drug development company Sareum announced on Thursday that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent on an invention associated with its proprietary 'SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme'.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.